Literature DB >> 22301508

Multimodal stepped care approach with acupuncture and PPAR-α agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain.

David J Kopsky1, Jan M Keppel Hesselink.   

Abstract

Central neuropathic pain is a common debilitating symptom in patients with multiple sclerosis. Side effects of analgesics often limit reaching therapeutic dosages. In this case report, a 61-year-old woman with chronic central neuropathic pain due to multiple sclerosis is described. Acupuncture could only partly and temporarily reduce the pain. However, after adding the natural compound palmitoylethanolamide, a glial modulator and peroxisome proliferator-activated receptor-α agonist, pain reduction was more pronounced and the interval between acupuncture sessions could be increased. A multimodal stepped care approach is demonstrated, with acupuncture and palmitoylethanolamide both influencing non-neuronal cells, such as activated glial cells, which are key factors in the development and maintenance of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22301508     DOI: 10.1136/acupmed-2011-010119

Source DB:  PubMed          Journal:  Acupunct Med        ISSN: 0964-5284            Impact factor:   2.267


  14 in total

1.  PPARα agonists--an emerging concept in the management of neuropathic and visceral pain.

Authors:  Shailendra Kapoor
Journal:  Psychopharmacology (Berl)       Date:  2012-03-30       Impact factor: 4.530

Review 2.  Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.

Authors:  Stephen D Skaper; Laura Facci; Mariella Fusco; Maria Federica Della Valle; Morena Zusso; Barbara Costa; Pietro Giusti
Journal:  Inflammopharmacology       Date:  2013-11-01       Impact factor: 4.473

Review 3.  Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.

Authors:  Stephen D Skaper; Laura Facci
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

Review 4.  Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.

Authors:  Stephen D Skaper; Laura Facci; Pietro Giusti
Journal:  Mol Neurobiol       Date:  2013-06-28       Impact factor: 5.590

Review 5.  Mast cells, glia and neuroinflammation: partners in crime?

Authors:  Stephen D Skaper; Laura Facci; Pietro Giusti
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

Review 6.  Acupuncture and multiple sclerosis: a review of the evidence.

Authors:  H I Karpatkin; D Napolione; B Siminovich-Blok
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-18       Impact factor: 2.629

7.  Electroacupuncture Promotes Remyelination after Cuprizone Treatment by Enhancing Myelin Debris Clearance.

Authors:  Keying Zhu; Jingxian Sun; Zheng Kang; Zaofeng Zou; Gencheng Wu; Jun Wang
Journal:  Front Neurosci       Date:  2017-01-10       Impact factor: 4.677

Review 8.  Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines?

Authors:  Caroline M Freitag; Richard J Miller
Journal:  Front Cell Neurosci       Date:  2014-08-20       Impact factor: 5.505

Review 9.  Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy.

Authors:  Linda Gabrielsson; Sofia Mattsson; Christopher J Fowler
Journal:  Br J Clin Pharmacol       Date:  2016-06-29       Impact factor: 4.335

10.  PPAR-α acutely inhibits functional activity of ASICs in rat dorsal root ganglion neurons.

Authors:  Jing Wu; Jia-Jia Wang; Ting-Ting Liu; Yi-Mei Zhou; Chun-Yu Qiu; Ding-Wen Shen; Wang-Ping Hu
Journal:  Oncotarget       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.